Linezolid Pharmacia Corp

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 181-187

  Barrett, J F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFPODOXIME PROXETIL; CEFTRIAXONE; CLARITHROMYCIN; DICLOXACILLIN; DRUG ANALOG; E 3709; EPEREZOLID; EPEROZOLID; ERYTHROMYCIN; IMIPENEM; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; OXACILLIN; PNU 100480; RIFAMPICIN; SEROTONIN AGONIST; U 97456; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033755128     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Preliminary data from the San Francisco ICAAC meeting
2. In vitro antibacterial activity of U-100592 and U-100766, novel oxazolidinone antibiotics
3. In vivo efficacy evaluations of U-100592 and U-100766, new oxazolidinone antibiotics
4. Drug safety evaluation of U-100592 an oxazolidinone antibiotic in dogs and rats
5. Drug safety studies with a novel oxazolidinone, U-100766
6. In vitro spectrum and activity of U-100592 and U-100766, two novel oxazolidinones
7. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections
8. Activities of RPR-106972 (a new oral streptogramin), cefditoren (a new cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parental agents against 203 penicillin-susceptible and-resistant Pneumococci
9. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
10. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of streptococcus pneumoniae
11. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
12. In vitro activities of oxazolidione compounds U-100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis
13. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
14. U-100766 safety, toleration and pharmacokinetics after oral and intravenous (iv) administration
15. In vitro and in vivo activity of U-100592 and U-100766, novel oxazolidinone antimicrobial agents
16. Second International Symposium: Recent advances in the Chemistry of Anti-Infective Agents, Churchill College, Cambridge, UK
17. Oxazolidinones block translation initiation by binding to ribosomes
18. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
19. Synthesis and SAR of novel antibacterial oxazolidinones
20. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfoprostin-quinupristein against Staphlococcus aureus and Staphylococcus epidermidis
21. Activities of new oxazolidinone antimicrobials against enterococci
22. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multi-drug resistant enterococci
23. Susceptibility of 115 penicillin susceptible and -resistant pneumococci to two oxazolidinones compared to penicillin G, ceftriaxone, teicoplanin, vancomycin, rifampicin and imipenem
24. In vitro activities of U-100592 and U-100766 against Staphylococcus aureus and coagulase negative species of Staphylococcus
25. In vitro activity of oxazolidinone compounds U100592 (592) and U100766 (766) versus Staphylococcus aureus (SA) and Staphylococcus epidermidis (SE)
26. Comparative in vitro activities of vancomycin and the oxazolidinones U-100592 and U-100766 against 300 clinical staphylococcal isolates
27. Activity of oxazolidinones U-100592 and U-100766 in vitro against penicillin-resistant and cephalosporin-resistant strains of S pneumoniae
28. Synthesis of U-100592 and U-100766, two new oxazolidinone antibacterial agents in clinical trials for treatment of multiply resistant Gram-positive infections
29. In vitro activities of oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative staphylococcus species
30. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
31. Linezolid safety, tolerance and pharmacokinetics after intravenous dosing wtwice daily for 7.5 days
32. Linezolid safety, tolerance and pharmacokinetics after intravenous dosing twice daily for 14.5 days
33. Linezolid binds to the 50S ribosomal subunit and competes with the binding of eperezolid, chloramphenicol and lincomycin
34. The oxazolidinone linezolid inhibits translation initiation in bacteria
35. Absorption, distribution, metabolism, and excretion of the oxazolidinone antibiotic Linezolid (PNU-100766) in the Sprague Dawley rat
36. Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and syndercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susce
37. Linezolid, a new oxazolidinone, has activity in vitro and in macrophage culture system against Mycobacterium avium complex (MAC)
38. Linezolid compared with other macrolides against Pasteurella species
39. Deutsche Bank Research: US Investment Research: Pharmacia and Upjohn Deutsche Bank Research
40. Aiming to enter top 25 with direct sale of Genotropin at core: Mr Payne of P and U
41. P and U Zyvox surveillance program to provide resistance data to physicians
42. Zyvox (Linezolid), the first of a new class of antibiotics, shows activity against Gram-positive bacteria
43. Antibacterial drug discovery and development - Third International Summit (Part II), Princeton, NJ, USA
44. Morgan Stanley Dean Witter: US Investment Research
45. In vitro activity of linezolid with or without aminoglycosides against vancomycin-resistant enterococci
46. Recent developments with oxazolidinone antibiotics
47. Activity of linezolid and the ketolide HMT 3647 against recent North American surveillance isolates of streptococcus pneumoniae
48. Mechanism of action of the oxazolidinone antibacterial agents
49. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
50. Preliminary phase III data suggest new antibiotic ZYVOX (linezolid) is effective for the treatment of challenging Gram-positive bacterial infections
51. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586
52. Safety and tolerance of linezolid in phase II trials
53. New antibiotics against Gram-positive pathogens - Pharmacokinetic and pharmacodynamic characteristics
54. Phase III trials evaluate the safety of new antibiotic Zyvox (linezolid) in the treatment of Gram-positive bacterial infections
55. Pharmacia and Upjohn study suggests investigational new antibiotic Zyvox (linezolid) may result in faster hospital discharge when treating MRSA infections
56. Pharmacia and Upjohn submits European filing for new antibiotic Zyvoxa
57. Merrill Lynch: Global healthcare bulletin
58. FDA advisory committee recommends approval of Zyvox (linezolid) first antibiotic in a completely new class in 35 years
59. Antibacterial Drug Discovery and Development - Fifth International Summit Meeting, Princeton, NJ, USA
60. FDA approves Zyvox - The first antibiotic in a completely new class in 35 years: New treatment option for a significant public health challenge
61. Pathogen-resistant antibiotic indications questioned by FDA committee
62. Zyvox phase IV studies may support penicillin-resistant indications
63. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
64. Efficacy of linezolid in experimental otitis media
65. Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom
66. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections
67. Infectious Diseases - Ninth International Congress, Buenos Aires, Argentina
68. Merrill Lynch - Global Healthcare Bulletin
69. Clinical Microbiology and Infectious Diseases - Tenth European Congress Stockholm, Sweden
70. New antibiotic addresses challenge of treating gram-positive bacterial infections; May help patients leave hospital sooner
71. Emergence of linezolid-resistance in Enterococcus faecium
72. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae
73. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniea
74. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci
75. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci
76. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium
77. Linezolid activity compared to those of selected macrolides and other agents againts aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans
78. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766)
79. The in vitro activity of linezolid (U-100766) and tentative breakpoints
80. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium
81. Synthesis and structure-activity relationships of new tropone-substituted oxazolidinone antibacterial agents